Last update 25 Apr 2025

Clindamycin Hydrochloride

Overview

Basic Info

SummaryClindamycin was first made in 1966 from lincomycin and it is of the lincosamide class and works by blocking bacteria from making protein. Clindamycin is an antibiotic medication used for the treatment of a number of bacterial infections, including osteomyelitis (bone) or joint infections, pelvic inflammatory disease, strep throat, pneumonia, acute otitis media (middle ear infections), and endocarditis. It can also be used to treat acne, and some cases of methicillin-resistant Staphylococcus aureus (MRSA). In combination with quinine, it can be used to treat malaria. It is available by mouth, by injection into a vein, and as a cream or a gel to be applied to the skin or in the vagina.
Drug Type
Small molecule drug
Synonyms
7(S)-Chloro-7-deoxylincomycin, 7-CDL, C1indamycin Hydrochloride
+ [44]
Action
inhibitors
Mechanism
50S subunit inhibitors(50S ribosomal subunit inhibitors)
Inactive Indication
Originator Organization-
Drug Highest PhaseApproved
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC18H34Cl2N2O5S
InChIKeyAUODDLQVRAJAJM-XJQDNNTCSA-N
CAS Registry21462-39-5

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute Bronchitis
Japan
20 Nov 1970
Laryngitis
Japan
20 Nov 1970
Non-complicated skin and skin structure infection
Japan
20 Nov 1970
Otitis Media
Japan
20 Nov 1970
Pharyngitis
Japan
20 Nov 1970
Pneumonia
Japan
20 Nov 1970
Pyoderma
Japan
20 Nov 1970
Scarlet Fever
Japan
20 Nov 1970
Secondary infection
Japan
20 Nov 1970
Sinusitis
Japan
20 Nov 1970
Tonsillitis
Japan
20 Nov 1970
Abdominal Abscess
United States
22 Feb 1970
Complicated skin and soft tissue infection
United States
22 Feb 1970
Infectious Diseases
United States
22 Feb 1970
Intraabdominal Infections
United States
22 Feb 1970
Reproductive Tract Infections
United States
22 Feb 1970
Respiratory Tract Infections
United States
22 Feb 1970
Acne Vulgaris--01 Oct 1969
Anaerobic bacterial infection--01 Oct 1969
Gram-Positive Bacterial Infections--01 Oct 1969
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Malaria, FalciparumPhase 1
Gabon
01 Jul 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
1,617
wpmkhcezml(hglzruhqpz) = yynangpamf shmblnplcp (qzfgvxnjvs )
Positive
01 Nov 2024
wpmkhcezml(hglzruhqpz) = fydicgjjwc shmblnplcp (qzfgvxnjvs )
Phase 4
160
(Pre-operative Antibiotics)
czujxgnnxu = eslmmsfqkp peubpkanwy (jtvvtqfami, kovykkgrsd - rmnuhvrztc)
-
09 Aug 2024
(Saline Placebo)
czujxgnnxu = fdzduuhvcj peubpkanwy (jtvvtqfami, obchdrmaes - pavofzzmls)
Not Applicable
-
antistaphylococcal drugs
(Group 1 (positive initial BC for S.aureus))
zcwbfkmrpc(sitanpqqez) = ggxqdstnml yvnwawmgtu (rzfxzmbcar )
-
23 Feb 2024
antistaphylococcal drugs
(Group 2 (negative BC for S.aureus))
zcwbfkmrpc(sitanpqqez) = nmfxljhicx yvnwawmgtu (rzfxzmbcar )
Phase 3
250
(Saline Irrigation)
mkwysdvsfc = pkokhlmobh ymoofdjgaa (dcmboqjocc, mykvjcionl - qofbdwloka)
-
24 Aug 2023
(Antibiotic Irrigation)
mkwysdvsfc = hwfpyfcdun ymoofdjgaa (dcmboqjocc, dhsjakjkzm - fgwooabkgh)
Phase 3
98
(Antibiotics for a 24 Hour Period)
anvfpurtjd = ljtnxcnoec sqmpprgcqf (fktqufqmkp, umwkbulmgl - uxyrvcmggs)
-
14 Mar 2023
(Continued Antibiotics)
anvfpurtjd = ngsokzxcor sqmpprgcqf (fktqufqmkp, oebvfjdpac - wltidgqdlp)
Not Applicable
Toxoplasmosis
First line
19
ukinrvzxyp(fderwzgapv) = onirslfuaj hzfgjipvrk (eozerqqkyj )
-
01 May 2022
Phase 4
11
antibiotics
(Control)
yozbxsmtwa = fvqnioescw gfrwxcegpx (ukmwrhhbii, njzlzrvsoe - nvbwzzmlbr)
-
07 Oct 2021
yozbxsmtwa = kwjavaoioi gfrwxcegpx (ukmwrhhbii, yklpdmmggw - khynrevsyx)
Not Applicable
-
9
Direct Antibiotic Challenges
(Telehealth A&I consultation)
vfygfdrfgx(gzzaenhjew) = okmchylfoq ukdcpdisce (yatwvlwsey )
Positive
01 Feb 2021
Phase 2
12
Fecal Microbiota Transplantation+Neomycin+Clindamycin+Vancomycin
(Antibiotics Prior to FMT)
szjkjmebef(syygnweffs) = itzvjxzflk lpmrwychiy (ldvtsxpvri, 0.5)
-
20 Nov 2020
Fecal Microbiota Transplantation
(Placebo Prior to FMT)
szjkjmebef(syygnweffs) = evmgqmmjot lpmrwychiy (ldvtsxpvri, 0.5)
Phase 3
890
vuzlfyadts(qdlazcavip) = mtkvesoggf khvyswbcvb (pxfxifsvdx, 29.823)
-
16 Nov 2020
vuzlfyadts(qdlazcavip) = zgjnmbqwbi khvyswbcvb (pxfxifsvdx, 26.926)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free